Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
m (Jwarner moved page Encorafenib (LGX818) to Encorafenib (Braftovi): FDA approval) |
m |
||
| Line 2: | Line 2: | ||
Class/mechanism (from [http://www.cancer.gov/drugdictionary?CdrID=712549 NCI Drug Dictionary]): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. | Class/mechanism (from [http://www.cancer.gov/drugdictionary?CdrID=712549 NCI Drug Dictionary]): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. | ||
| − | = | + | =Diseases for which it is used= |
| − | + | *[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]] | |
| − | * | + | |
| + | =History of changes in FDA indication= | ||
| + | *6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] "for patients with unresectable or metastatic [[Melanoma,_BRAF-mutated|melanoma with a BRAF V600E or V600K mutation]], as detected by an FDA-approved test." | ||
| + | |||
| + | =Also known as= | ||
| + | *'''Code name:''' LGX818 | ||
| + | *'''Brand name:''' Braftovi | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| Line 13: | Line 18: | ||
[[Category:BRAF inhibitors]] | [[Category:BRAF inhibitors]] | ||
| − | [[Category: | + | [[Category:Melanoma medications]] |
| + | |||
| + | [[Category:Drugs FDA approved in 2018]] | ||
Revision as of 23:49, 27 June 2018
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Binimetinib (Mektovi) "for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test."
Also known as
- Code name: LGX818
- Brand name: Braftovi